Grant: Canadian Lung Association Research Fellowship
McMaster University
$50,000.00
Mepolizumab for the Treatment of Chronic Cough with Eosinophilic Airways Disease
FY 2022-23
Summary
This is the first ever double blind, randomized, placebo-controlled study to investigate the role of depleting eosinophils using biologic therapy in the treatment of chronic cough secondary to eosinophilic lung disease.
Chronic cough affects approximately 10% of the general population. Unfortunately, there are no licensed treatments for this debilitating condition, which affects the social, physical and psychological well-being of patients. Asthma and Non-asthmatic
Eosinophilic Bronchitis (NAEB) are known causes of chronic cough. An important feature of both these conditions is the presence of an inflammatory cell called the eosinophil which is found in the airways. The most common treatment for this is high doses of inhaled steroids, but when the cough becomes unbearable, repeated courses of oral steroids are administered. However, many patients have persistent cough despite this treatment and can develop significant steroid related side effects. Developing treatment for this condition is thus a major unmet clinical need. Cough is a defensive
reflex which is triggered by activation of nerves which are found in the airway lining. Recent evidence suggests there is a significant increase in eosinophils in the airways which sensitizes these nerves. This makes the nerves more easily activated leading to more coughing. If these eosinophils could be depleted and prevented to enter the airways, then we predict that the nerves will be less sensitive and coughing will be reduced.
Mepolizumab is an injection medication, which blocks a key chemical that prevents the maturation and activation of eosinophils. It is a licensed medication which is currently used in patients with severe asthma to prevent severe asthma attacks. However, there has been no evidence to show whether this medication would improve coughing. The aim of this research proposal is to investigate whether mepolizumab reduces objective cough frequency in patients with eosinophilic airway diseases.
This is a 9-visit randomized, double-blind, placebo-controlled study evaluating the effectiveness of 4 doses of mepolizumab for the treatment of chronic cough in patients with eosinophilic airways disease.
Chronic cough has a highly unmet research need. With the increasing prevalence of chronic cough in Canada, it is important to establish new treatments with reduced side effects to patients. The results of this study would result in a paradigm shift in the management of this challenging condition and provide patients hope of an improved quality of life.
Department
Program
Canadian Lung Association Research Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
477059
Name
Diab Nermin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Lung Association (Ottawa)
Prcname2
Special Cases
Projecttitle
Mepolizumab for the Treatment of Chronic Cough with Eosinophilic Airways Disease
Programtype2
Salary Programs
Orgnameinp2
McMaster University
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Canadian Lung Association Research Fellowship
Keyworddelim
Airway Disease; Asthma; Chronic Cough; Eosinophilic Bronchitis; Type Ii Inflammation
Abstract
This is the first ever double blind, randomized, placebo-controlled study to investigate the role of depleting eosinophils using biologic therapy in the treatment of chronic cough secondary to eosinophilic lung disease.
Chronic cough affects approximately 10% of the general population. Unfortunately, there are no licensed treatments for this debilitating condition, which affects the social, physical and psychological well-being of patients. Asthma and Non-asthmatic
Eosinophilic Bronchitis (NAEB) are known causes of chronic cough. An important feature of both these conditions is the presence of an inflammatory cell called the eosinophil which is found in the airways. The most common treatment for this is high doses of inhaled steroids, but when the cough becomes unbearable, repeated courses of oral steroids are administered. However, many patients have persistent cough despite this treatment and can develop significant steroid related side effects. Developing treatment for this condition is thus a major unmet clinical need. Cough is a defensive
reflex which is triggered by activation of nerves which are found in the airway lining. Recent evidence suggests there is a significant increase in eosinophils in the airways which sensitizes these nerves. This makes the nerves more easily activated leading to more coughing. If these eosinophils could be depleted and prevented to enter the airways, then we predict that the nerves will be less sensitive and coughing will be reduced.
Mepolizumab is an injection medication, which blocks a key chemical that prevents the maturation and activation of eosinophils. It is a licensed medication which is currently used in patients with severe asthma to prevent severe asthma attacks. However, there has been no evidence to show whether this medication would improve coughing. The aim of this research proposal is to investigate whether mepolizumab reduces objective cough frequency in patients with eosinophilic airway diseases.
This is a 9-visit randomized, double-blind, placebo-controlled study evaluating the effectiveness of 4 doses of mepolizumab for the treatment of chronic cough in patients with eosinophilic airways disease.
Chronic cough has a highly unmet research need. With the increasing prevalence of chronic cough in Canada, it is important to establish new treatments with reduced side effects to patients. The results of this study would result in a paradigm shift in the management of this challenging condition and provide patients hope of an improved quality of life.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Diab, Nermin
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $50,000~ $0~